DK3491014T5 - Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant - Google Patents

Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant Download PDF

Info

Publication number
DK3491014T5
DK3491014T5 DK17754224.8T DK17754224T DK3491014T5 DK 3491014 T5 DK3491014 T5 DK 3491014T5 DK 17754224 T DK17754224 T DK 17754224T DK 3491014 T5 DK3491014 T5 DK 3491014T5
Authority
DK
Denmark
Prior art keywords
gpr156
allele
variant
nucleic acid
acid molecule
Prior art date
Application number
DK17754224.8T
Other languages
Danish (da)
English (en)
Other versions
DK3491014T3 (da
Inventor
Claudia Gonzaga-Jauregui
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of DK3491014T3 publication Critical patent/DK3491014T3/da
Application granted granted Critical
Publication of DK3491014T5 publication Critical patent/DK3491014T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
DK17754224.8T 2016-07-28 2017-07-28 Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant DK3491014T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (2)

Publication Number Publication Date
DK3491014T3 DK3491014T3 (da) 2023-05-30
DK3491014T5 true DK3491014T5 (da) 2024-09-02

Family

ID=59649989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17754224.8T DK3491014T5 (da) 2016-07-28 2017-07-28 Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant

Country Status (13)

Country Link
US (4) US10266582B2 (enExample)
EP (2) EP4230648A3 (enExample)
JP (2) JP7556688B2 (enExample)
KR (2) KR102661616B1 (enExample)
CN (1) CN109563516B (enExample)
AU (1) AU2017302611B2 (enExample)
CA (1) CA3032124A1 (enExample)
DK (1) DK3491014T5 (enExample)
IL (1) IL264473A (enExample)
MX (2) MX2019001084A (enExample)
NZ (1) NZ751010A (enExample)
SG (1) SG11201900738YA (enExample)
WO (1) WO2018022967A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020150426A1 (en) * 2019-01-17 2020-07-23 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
EP0879241A4 (en) 1995-11-21 2000-04-19 Icn Pharmaceuticals INHIBITION OF TUMOR GROWTH BY ANTISENSE OLIGONUCLEOTIDES FOR IL-8 AND THE IL-8 RECEPTOR
EP1007655A1 (en) 1996-02-15 2000-06-14 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
AU2001255397A1 (en) * 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
AU2013262709A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
SI3401400T1 (sl) 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
BR112018012744A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método de fabricação de um anel vaginal
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도

Also Published As

Publication number Publication date
AU2017302611B2 (en) 2021-12-09
IL264473A (en) 2019-02-28
CN109563516B (zh) 2023-10-27
DK3491014T3 (da) 2023-05-30
US11155598B2 (en) 2021-10-26
NZ751010A (en) 2024-11-29
MX2024013403A (es) 2024-12-06
KR20240027874A (ko) 2024-03-04
EP4230648A2 (en) 2023-08-23
EP4230648A3 (en) 2023-10-18
CA3032124A1 (en) 2018-02-01
CN109563516A (zh) 2019-04-02
US20220073589A1 (en) 2022-03-10
US10562953B2 (en) 2020-02-18
JP2019527229A (ja) 2019-09-26
JP7556688B2 (ja) 2024-09-26
KR20190034532A (ko) 2019-04-02
US20190202891A1 (en) 2019-07-04
JP2023071704A (ja) 2023-05-23
EP3491014B1 (en) 2023-04-05
WO2018022967A1 (en) 2018-02-01
KR102661616B1 (ko) 2024-04-30
SG11201900738YA (en) 2019-02-27
AU2017302611A1 (en) 2019-03-14
US10266582B2 (en) 2019-04-23
MX2019001084A (es) 2019-06-10
EP3491014A1 (en) 2019-06-05
US20200231651A1 (en) 2020-07-23
US20180030114A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
DK3529357T3 (da) Fremgangsmåder til stregkodning af nukleinsyremolekyler fra individuelle celler
DK3507366T3 (da) Kemisk modificeret, enkeltstrengede rna-modificerende oligonukleotider
DK3129487T3 (da) Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
KR102349259B9 (ko) 친화성 시약을 이용한 핵산 시퀀싱
LT3334841T (lt) Nukleorūgščių tyrimo būdai
DK3459315T3 (da) Fremgangsmåde til direkte adgang til drift med flere numerologier
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
PL3118311T3 (pl) Antysensowny kwas nukleinowy
LT3294325T (lt) Car modifikuotų t ląstelių poveikio sustiprinimas nukleorūgšties vakcinacijos dėka
EP3274471A4 (en) Polymer tagged nucleotides for single molecule electronic snp assay
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
DK3491014T5 (da) Allel-specifik primer eller sonde, som er hybridiseret til et nucleinsyremolekyle, som koder for en GPR156 variant
DK3425055T3 (da) Molekylært detekterings-/diagnosereagens til tumor
LT3134536T (lt) Sistemos ir būdai, skirti nukleorūgščių brūkšniniam kodavimui
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
DK3699289T3 (da) Prøveklargøring til nukleinsyreamplifikation
DK3250586T3 (da) Hidtil ukendte proteiner, som er specifikke for angiogenese
EP3134550A4 (en) High-throughput structure determination using nucleic acid calipers
IT201600117287A1 (it) Metodo di trasfezione transiente per produzione retrovirale.
DK3224268T3 (da) Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
DK3126052T3 (da) Biokemisk reaktionssystem
DK3283643T3 (da) Midler til diagnosticering, forudsigelse eller monitorering af Pneumocystis pneumoni
EP3350191A4 (en) nucleotide analogs